AnKuo Biopharma

AnKuo Biopharma (岸阔医药) is a Chinese biopharmaceutical company that appears in elsewhere's corpus mainly through its financings as a FreeS Fund portfolio company. FreeS first participated in its Series A in September 2019, then doubled down in a US$20 million Series A+ round announced in April 2021, which brought in Jade Capital (拾玉资本) and Sinovation Ventures as new shareholders while existing backers Matrix Partners China, BioTrack Capital (博远资本) and Guoke Jiahe also followed on . Per a FreeS research piece, it was among FreeS's biotech holdings that stayed resilient through the 2022 capital downturn, completing at least one financing round that year . Beyond its funding record, elsewhere's corpus doesn't cover the company's pipeline or therapeutic focus in detail.